Judicial Review Leave: Wide Drug-Funding Discretion Does Not Exclude Scrutiny of Material Medical Evidence

1. Introduction

The High Court granted a child permission to challenge the Health Service Executive’s refusal to supply Wegovy under the exceptional arrangements permitted by section 23 of the Health (Pricing and Supply of Medical Goods) Act 2013. The central issue was whether potentially significant evidence of a rare syndrome had been overlooked or discounted when the HSE assessed the child’s circumstances.

The decision concerns leave to seek judicial review, not the ultimate legality of the refusal. The Court did not establish an entitlement to Wegovy, determine that another medicine was unsuitable, or direct the HSE to fund treatment. Its narrower conclusion was that broad statutory discretion and public-resource considerations did not make the proposed challenge unarguable.

The judgment illustrates the distinction between judicial interference with healthcare allocation and judicial supervision of the factual basis on which an individual funding decision is made.

2. Background and Procedural History

The applicant was a teenager represented by his mother as next friend. The evidence described severe obesity, hyperphagia, autism, cardiovascular difficulties and orthopaedic complications. A consultant clinical geneticist had expressed the opinion that a rare syndrome was clinically evident. The syndrome’s possible relevance to the applicant’s condition became central to the challenge.

The child was prescribed Wegovy in July 2025. The evidence indicated substantial weight loss and improvements in behaviour, independence and exercise. His mother, a full-time carer with limited financial resources, had been paying approximately €450 monthly for the medicine but could not continue doing so.

Although the applicant held a medical card, Wegovy was not generally reimbursable under the relevant medical or community drug schemes. His medical-card status therefore did not itself establish an entitlement to the medicine.

The original proceedings were brought before an application had been made under the statutory provision ultimately relied upon. The Court adjourned the matter, without objection from the HSE, to allow that application to be made. On 27 January 2026, the applicant’s mother sought an individual discretionary arrangement under section 23. The HSE refused the application on 19 May 2026, and the proceedings were reframed to challenge that refusal.

The renewed application concerned Wegovy. Earlier references to Ozempic were explained by the fact that both products contain semaglutide, but the Court confined this leave application to the medicine identified in the current prescription and application.

3. Summary of the Decision

The Court held that the applicant had an arguable case that the HSE had failed to address a potentially material aspect of his medical circumstances. That omission could matter both to the suitability of the proposed alternative medicine and to the HSE’s concern that an exceptional funding decision might affect many other patients.

The operative outcome was:

• Leave granted to seek certiorari quashing the refusal dated 19 May 2026.
• Leave granted for the residual request for such other relief as the Court considered just.
• Leave refused for the specifically formulated declarations concerning the suitability of the alternative medicine, because those declarations were unnecessary to the challenge.

The refusal of leave for those declarations was not a finding that the alternative medicine was suitable. Relevant arguments could still support the challenge to the refusal, and any necessary declaration could be considered after a full hearing through the residual relief.

The judgment also recorded an earlier exceptional order allowing the applicant to commence proceedings without paying court stamp duty.

4. The Statutory Framework

Section 17 of the 2013 Act requires the HSE to establish a reimbursement list. Section 23 provides a separate route for supplying an item to an individual patient notwithstanding that it is not listed. It permits the HSE, at its discretion and subject to appropriate conditions, to make arrangements under section 59 of the Health Act 1970 where satisfied that:

“(a) the patient requires that item for clinical reasons, and

(b) there is no listed item which is a suitable alternative for that item in so far as that patient is concerned.”

This is an individual exception, not necessarily a mechanism for generally listing a medicine. The statutory wording makes the patient’s particular circumstances relevant, especially when assessing whether a listed alternative is suitable.

Nevertheless, the Court recognised that the two clinical requirements are conditions precedent to exercising the discretion. Satisfying them does not automatically compel supply. The applicant’s arguable case was instead that the discretion had to be exercised on a properly informed factual basis.

5. Legal Reasoning

5.1 The limited question at the leave stage

The HSE opposed leave on the basis that the challenge had no prospect of succeeding. The Court therefore had to decide whether the case was arguable, not whether the applicant had already proved that the refusal was unlawful.

That distinction was decisive. The Court was not required to resolve disputed evidence, determine the definitive medical significance of the syndrome, or settle the precise limits of review of the HSE’s discretion. Those matters could require fuller examination at the substantive hearing.

5.2 Broad discretion does not mean immunity from review

The HSE emphasised the breadth of section 23, its knowledge of public healthcare needs and budgets, and the policy-like character of reimbursement decisions. It accepted that the power was reviewable but argued that judicial intervention would be confined to arbitrary or capricious decision-making.

The Court acknowledged the need for restraint. Judges cannot fairly redistribute public resources by considering one patient’s needs without access to the competing demands faced by the HSE. However, that does not necessarily prevent a court from examining whether a decision ignored or irrationally discounted a relevant consideration.

The judgment thus distinguished substituting a funding decision from reviewing the lawfulness of the decision-making process. The former would raise serious institutional concerns; the latter remained arguable on the evidence presented.

5.3 Why the syndrome evidence could be material

The refusal expressly proceeded by reference to three named conditions, the availability of an alternative medicine, and the potential implications for other patients. The rare syndrome was not substantively addressed.

The Court identified two possible consequences of that omission:

• Clinical suitability: the syndrome might affect whether the proposed alternative was suitable for this particular patient.
• Wider financial implications: the rarity of the syndrome might affect the assumption that granting the application would have implications for a substantial number of other patients.

Neither proposition was established as fact. The Court’s point was that the evidence might materially alter the analysis, making the proposed challenge unsuitable for rejection at the permission stage.

5.4 Uncertainty about what the decision-makers received

A significant factual issue concerned whether the consultant’s letter had actually been before the relevant decision-makers. The HSE submitted orally that the syndrome evidence had not been provided to them. However, the written refusal referred to pending genetic testing and stated that the decision-makers had examined court papers. The clinical letter had been exhibited in the initial proceedings.

The Court identified two possible scenarios. If the decision-makers had the letter, the question was whether they had failed to consider or explain their treatment of potentially material evidence. If they did not have it with the latest application, questions could arise about procedural fairness, the transmission of information and evidential responsibilities.

The judgment did not equate the HSE’s possession of litigation documents with proof that every decision-maker had considered them. Instead, it held that the documentary references and procedural history supplied an arguable basis for further inquiry. The Court declined to resolve those factual uncertainties at leave stage.

5.5 The possible remedy preserves administrative responsibility

If the challenge ultimately succeeds, a possible outcome is that the refusal will be quashed and returned to the HSE for reconsideration on an accurate factual basis. That would not itself require the HSE to supply Wegovy. It would leave the substantive funding decision with the statutory decision-maker, subject to lawful exercise of its powers.

6. Precedents Cited and Their Influence

G v. D.P.P. [1994] 1 I.R. 374

This Supreme Court authority supplied the established framework for leave applications. The applicant must show that judicial review is the appropriate remedy and bears the burden of establishing an arguable case. It directed attention to whether the proposed challenge should proceed, rather than whether it should already succeed.

O'Doherty v. Minister for Health [2022] IESC 32, [2023] 2 IR 488

Drawing on O’Donnell C.J.’s reasoning, Gearty J. explained that an applicant needs an arguable prospect of success, not a reasonable prospect of success. The distinction prevented the leave hearing from becoming a premature determination of a difficult dispute about statutory discretion and medical evidence.

Amariei v. Chief Appeals Officer [2026] IESC 22, [2025] 2 ILRM 335

The Court relied on Donnelly J.’s statement that, at leave stage, the applicant’s case must be taken at its highest. This supported allowing the challenge to proceed despite unresolved questions about the clinical letter. It did not remove the applicant’s eventual obligation to establish the factual and legal basis of the challenge.

Garda Representative Association v Minister for Finance [2010] IEHC 78

This was the HSE’s principal authority for restraint. Charleton J.’s judgment recognised that decisions approaching political or policy choices attract particular judicial caution. It also distinguished genuine discretionary powers from statutory arrangements in which satisfaction of detailed criteria may effectively create an entitlement.

Gearty J. did not treat section 23 as creating an automatic entitlement. Instead, she distinguished the present challenge because it concerned a potentially deficient factual foundation, rather than simply disagreement with policy. The earlier judgment’s recognition that a failure to consider a submission could be unlawful left room for argument about failure to consider a material component of an individual patient’s submission.

The Court also noted that the earlier case had been decided after a full hearing. It expressly treated that procedural distinction as neither decisive nor necessarily significant, rather than as an independent reason to grant leave.

O'Reilly v Limerick Corporation [1989] ILRM 181

Discussed through the extensive quotation in the Garda Representative Association judgment, this authority concerned the distribution of housing funds and the limits of judicial review of resource-allocation choices. It reinforced the HSE’s submission that courts are poorly placed to compare competing demands on public expenditure.

Its influence was therefore cautionary. It did not resolve whether an individual statutory decision could arguably be unlawful because potentially important evidence had not been addressed.

B.M. v Chief Appeals Officer [2024] IESC 51

This Supreme Court decision supported the principle that judges should not substitute their own allocation decisions for those of public bodies with access to the relevant resource information. The present Court accepted that limitation.

It nevertheless distinguished the authority because there was no comparable omission of potentially material evidence in the challenge concerning a limited carer’s allowance. The proposed challenge here concerned the integrity of the factual assessment, rather than a judicial reassessment of the appropriate allocation.

Duff v Minister for Agriculture [1997] 2 IR 22

This authority appeared through the discussion in Administrative Law in Ireland. The textbook identified it as illustrating the dominant view that discretionary powers are reviewable. Its relevance was to resist any equation between a wide discretion and complete immunity from judicial supervision.

The Court considered that proposition alongside the textbook’s warning about resource-allocation litigation. Together, they showed why the legal position required fuller consideration rather than summary rejection at leave stage.

Airey v Ireland (1979) 2 EHRR 305

This European Court of Human Rights decision informed the stamp-duty ruling. It established an Article 6 violation arising from the absence of legal aid for judicial-separation proceedings and illustrated the principle that economic barriers must not make access to justice ineffective.

The judgment did not derive a general right to free litigation from this authority. It used the access-to-justice principle in assessing the applicant’s particular financial circumstances.

Murphy v Minister for Justice [2001] 2 ILRM 144

This authority supported the legitimacy of reasonable court fees and had refused an exemption from modest stamp duty. Gearty J. distinguished it by reference to the evidence of unavailable legal aid, the present applicant’s limited means, the public-interest dimension and the child’s health.

The resulting exemption was expressly exceptional. It did not displace the ordinary requirement to pay court fees.

7. Access to Justice and the Child’s Circumstances

The stamp-duty exemption rested on affidavit evidence of income, expenditure and caring responsibilities. Even a modest fee would impose a significant burden in the circumstances. The combination of financial hardship, unavailable legal aid and the proceedings’ subject matter justified the exceptional direction.

The applicant’s mother also relied on Article 42A of the Constitution when distinguishing the earlier fees authority. The judgment records that submission, but does not formulate a general constitutional rule exempting children’s proceedings from fees or requiring funding of a particular medicine.

The two aspects of the judgment should therefore remain distinct: financial hardship supported access to the court, while the arguable omission of medical evidence supported permission to challenge the HSE’s decision.

8. Potential Impact

The judgment’s principal significance is procedural and supervisory, rather than an expansion of substantive drug entitlements.

• Individual evidence matters: decision-makers assessing exceptional funding applications should address medical evidence capable of affecting the statutory criteria.
• Resource arguments remain available: the HSE may consider budgets and wider consequences, but assumptions about those consequences may require examination where an applicant identifies materially distinguishing circumstances.
• Clear records assist review: identifying the evidence received and explaining the treatment of important clinical material can reduce uncertainty about the decision’s factual foundation.
• Permission is not victory: an arguable evidential omission may justify a full hearing without establishing irrationality, entitlement or a right to reimbursement.
• Applicants should document their cases carefully: the unresolved question about transmission of the clinical letter highlights the practical importance of submitting relevant evidence directly and retaining proof of submission.

The decision does not establish that rarity alone warrants exceptional funding, that clinical benefit overrides all resource considerations, or that Wegovy must be preferred to the proposed alternative. Those propositions were not decided.

9. Complex Concepts Simplified

Leave to seek judicial review

Permission to bring a public-law challenge. The applicant must present an arguable case, not prove the entire claim at this preliminary stage.

Certiorari

An order quashing an unlawful decision. It commonly leads to reconsideration rather than the court making the administrative decision itself.

Statutory discretion

A legally conferred power to choose between permitted outcomes. Its breadth does not necessarily remove legal controls over its exercise.

Condition precedent

A requirement that must be satisfied before a power can be exercised. Meeting section 23’s clinical requirements does not automatically compel the HSE to supply the item.

Material consideration

Information capable of affecting the decision. Here, the syndrome evidence might influence the assessment of treatment alternatives and wider funding implications.

Rationality review

Judicial examination of whether a decision is legally defensible, rather than whether the judge would have reached a different clinical or financial conclusion.

Next friend

A person who conducts proceedings on behalf of a child. The child remains the applicant whose interests are represented.

10. Conclusion

The judgment preserves both administrative responsibility and judicial oversight. The HSE retains broad discretion over exceptional drug supply, but a potentially material omission in the assessment of an individual patient can justify permission to challenge its decision.

The applicant secured a full hearing, not a right to Wegovy. The substantive questions—what evidence the decision-makers had, how they treated it, and whether the refusal was unlawful—remain to be determined.